Oligodendrocytes and OPCs: one supplier publishes a price, and that is the finding

The buying problem here is not price. It is that there is only one price.

Across the suppliers that publish any glial figure at all, exactly one, bit.bio, carries a catalogue price for the oligodendrocyte lineage. Axol and iXCells both publish astrocyte prices on public store APIs and both returned nothing for oligodendrocytes or OPCs when queried on 2026-09-01. A buyer who needs a second quote is not comparing pages; they are opening a sales conversation and waiting.

That changes what procurement diligence looks like. With two or three published prices you compare. With one, the only available check is internal consistency, how the single supplier prices this lineage against its own other lineages, plus a specification list rigorous enough that a quoted competitor has to answer the same questions.

The one published price

Three observations, all of which are checkable against the catalogue rather than inferred.

The OPC and the oligodendrocyte-like cell are the same price. io1028S and io1100S are both 999 for the same pack size. The supplier does not charge for the extra differentiation time between progenitor and oligodendrocyte-like cell, which means the choice between them is a scientific one and not a budgetary one.

The engineered background is free. The CRISPRko-Ready line io1095S sits at 999, identical to wild type. This matches the pattern in the same supplier’s microglia range, where reporter and CRISPR-ready backgrounds also carry no premium.

The pack size is smaller than the glial norm. Each oligodendrocyte vial is stated at more than 1 million viable cells, against more than 1.5 million for the same supplier’s microglia at the same 999. That is where the lineage premium hides, and it is worth extracting.

The lineage premium is real and it is about 50 percent

Comparing bit.bio SKUs to bit.bio SKUs removes supplier and currency as variables, which is the only clean comparison available in a single-price category.

All four rows are from the ioCells 2026 catalogue (BB/IOCC/V8), recorded 2026-09-01. The headline price is identical across all four products. What changes is how many cells you get for it.

Astrocytes and microglia both land near 333 per million viable cells. Oligodendrocyte-lineage cells land near 500 per million, roughly 50 percent more per million for the same headline figure. A buyer reading only the price column would conclude the four products cost the same. They do not.

This is the argument for always reducing a cell quote to a per-viable-million figure before comparing anything, and it is the argument for demanding viable counts rather than counts at freeze. bit.bio states viable counts explicitly, which makes this arithmetic honest. Any supplier asked to bid against these figures should be required to answer in the same units.

Why the lineage costs more, and why that is not a supplier problem

Oligodendrocyte differentiation is long and it is the last major neural lineage to be brought under reliable protocol control.

The published methods make the scale of the problem visible. A 2026 Cells paper describes generating functional OPCs through serial replating of iPSC-derived neural progenitor spheroids (PMC13297427), a multi-stage route through a 3D intermediate, not a two-week directed differentiation. A Bio-protocol article sets out a human iPSC-derived neuron and oligodendrocyte co-culture configured as a small-molecule screening assay for myelination (PMC12067306), which is the downstream assay most buyers of this lineage are building towards. Work in Acta Neuropathologica Communications reports that the mGluR5 agonist CHPG enhances human oligodendrocyte differentiation (PMC12492762), which is a statement that differentiation efficiency remains an active pharmacological target rather than a solved parameter.

Taken together, that is a lineage where manufacturing yield is genuinely harder than it is for astrocytes. The 50 percent per-million premium is consistent with that. It is not evidence of overcharging, but neither is it evidence of a fair price, because there is nothing to compare against.

The cost that dwarfs the vial

Anyone budgeting an oligodendrocyte experiment from the vial price is budgeting the small number.

Myelination assays run long. The screening co-culture protocol cited above is a multi-week arrangement, and disease-model work in this lineage, for example the multiple sclerosis organoid study linking p21 to oligodendrocyte dysfunction (PMC13053263), runs on organoid timescales rather than monolayer ones. The real cost structure of the experiment is:

• The vial, at roughly 500 per million viable cells.
• The co-culture partner, because an oligodendrocyte with nothing to ensheath produces a marker panel rather than a phenotype.
• Weeks of medium, incubator space and technician attention across the maturation window.
• The imaging or readout capacity held open for the duration.

On a multi-week myelination assay the consumables and labour routinely exceed the cell cost. The procurement implication is direct: optimising the vial price is the wrong place to spend negotiating effort in this category. Optimising delivery timing, so that the culture starts on the week your incubator and imaging slots are free, is worth more.

What to do about having no second quote

Three practical routes, in descending order of usefulness.

Make the quoted supplier answer the published supplier’s questions. bit.bio publishes viable cell counts, pack composition and a per-SKU price. Any supplier quoting against it should state viable cells at release, not a count at freeze; state the pack composition; and state whether the price includes medium. If a quote comes back in different units, it is not a competing quote.

Ask explicitly for the stage, not the label. “Oligodendrocyte-like” and “OPC-like” are the supplier’s own hedged wording, and the hedge is honest, these are cells with the relevant lineage identity, not cells certified to myelinate. A quote for “oligodendrocytes” from a second supplier should be pinned to a stage, a marker set and a differentiation day before it is treated as comparable.

Consider whether the experiment needs human cells at this stage. Rodent OPCs are a mature, well-documented preparation with published bulk production and cryopreservation protocols (PMC12254587). They are not a scientific substitute for human oligodendrocytes in a human model, and nothing on this page should be read as suggesting they are. They are a substitute for burning human vials while you qualify a coating, a plate, an imaging pipeline or a new technician. The economics of that substitution are set out in rodent and immortalised lines.

Stage: OPC or oligodendrocyte-like cell

The two SKUs cost the same, so this decision should be made on the experiment.

Buy OPC-like cells when the biology you are studying is proliferation, migration, differentiation timing, or anything upstream of myelin production. An OPC that you differentiate yourself gives you the differentiation step as an experimental variable, which is the whole point if you are screening compounds that act on it.

Buy oligodendrocyte-like cells when the differentiation step is not the question and you want to start closer to the readout. You are buying time off the front of a long protocol, and at an identical price that is a straightforward gain.

Buy the CRISPRko-Ready line when you intend to knock a gene out. It costs the same as wild type, so the only reason not to take it is if you do not need it. Confirm what “ready” means in this supplier’s documentation before assuming your editing workflow drops straight in.

The one thing that cannot be bought at any price surveyed is a myelination specification. No supplier in this survey publishes an ensheathment or myelin-basic-protein threshold as a release criterion. If your programme depends on the cells myelinating an axon, that is something you demonstrate in your own hands with your own co-culture, and it should be budgeted as a qualification experiment before it is budgeted as a screen.

QC checklist

• Lot-specific certificate of analysis reviewed before you commit to the lot.
• Viable cell count at release, stated as viable rather than as a count at freeze, with the assay named.
• Post-thaw viability specification and the time point at which it is measured.
• Lineage marker panel run on this lot, distinguished from representative data on the product page. For OPCs ask which progenitor markers; for oligodendrocyte-like cells ask which maturation markers.
• Differentiation day or stage at cryopreservation, which determines how much protocol remains in front of you.
• The medium and coating the marker data was generated in, by catalogue number.
• Sterility and mycoplasma release testing with the method named.
• Whether the two vials in a pack are from the same manufacturing lot. In a two-vial pack this matters: if they are different lots, they are two experiments, not one.
• Shipping format and receiving procedure, dry ice or dry shipper, confirmed against what your site can actually accept.
• Storage temperature and maximum acceptable hold time on receipt.

Specification checklist for an oligodendrocyte or OPC quote

• Stage required: OPC-like or oligodendrocyte-like, stated against named markers rather than by label alone.
• The maturation endpoint the cells must reach, and the culture duration it implies. State this in the enquiry, because it changes which stage you should be buying.
• Whether myelination or ensheathment is a required outcome, and your acknowledgement that no supplier surveyed releases against it.
• Total viable cells required across the programme, in viable cells, with the pack count that follows.
• Genetic background: wild type, CRISPRko-Ready, or a disease genotype if the supplier can provide one.
• Co-culture partners, neurons, astrocytes, or both, and the delivery week all components must share.
• Medium and coating package, and whether the quote includes it.
• Currency the catalogue figure will be billed in, confirmed in writing where one number is published as valid in three currencies.
• Lot availability and production schedule, since a thinly supplied lineage is more likely to be made to order than picked from stock.
• Licence terms for anything downstream that will be sold rather than published.

Where to go next

The datasheet, unit, lead time and QC scope, is at ipsc-oligodendrocytes-opc. The wider glial price table and the published co-culture ratios are in iPSC astrocytes, microglia and glia, and the per-million arithmetic across the whole glial category is in astrocyte and glia pricing. If the destination is a neuronal co-culture, human iPSC cortical neurons covers the other half of the order.

How we can help

In a category with one published price, the work is not price comparison. It is making a quoted supplier answer in the same units as the published one, and confirming what stage you are actually buying. Tell us the stage, the viable-cell count, the maturation endpoint and the week the culture has to start, and we will source quotes, normalise them to viable cells per pack, confirm the billing currency in writing, and ask what the marker panel was run in.

Where the single catalogue item is the right answer, we will say so and tell you to order it directly.